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Abstract
Recent genome-wide association (GWA) studies of lipids have been conducted in samples
ascertained for other phenotypes, particularly diabetes. Here we report the first GWA analysis of
loci affecting total cholesterol (TC), low-density lipoprotein (LDL) cholesterol, high-density
lipoprotein (HDL) cholesterol and triglycerides sampled randomly from 16 population-based
cohorts and genotyped using mainly the Illumina HumanHap300-Duo platform. Our study
included a total of 17,797-22,562 persons, aged 18-104 years and from geographic regions
spanning from the Nordic countries to Southern Europe. We established 22 loci associated with
serum lipid levels at a genome-wide significance level (P < 5 × 10-8), including 16 loci that were
identified by previous GWA studies. The six newly identified loci in our cohort samples are
ABCG5 (TC, P = 1.5 × 10-11; LDL, P = 2.6 × 10-10), TMEM57 (TC, P = 5.4 × 10-10), CTCF-
PRMT8 region (HDL, P = 8.3 × 10-16), DNAH11 (LDL, P = 6.1 × 10-9), FADS3-FADS2 (TC, P =
1.5 × 10-10; LDL, P = 4.4 × 10-13) and MADD-FOLH1 region (HDL, P = 6 × 10-11). For three
loci, effect sizes differed significantly by sex. Genetic risk scores based on lipid loci explain up to
4.8% of variation in lipids and were also associated with increased intima media thickness (P =
0.001) and coronary heart disease incidence (P = 0.04). The genetic risk score improves the
screening of high-risk groups of dyslipidemia over classical risk factors.
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Serum lipids are important determinants of cardiovascular disease and are related to
morbidity1-3. The high heritability of circulating lipid levels is well established, and earlier
studies of individuals with extreme lipid values or families with mendelian forms of
dyslipidemias have exposed the involvement of numerous genes and respective proteins in
lipid metabolism1,4,5. Recent GWA studies mostly done in study samples enriched with
type 2 diabetes cases have implicated a total of 19 loci controlling serum high-density
lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL) and triglycerides
(TG)6-11. The loci include the genes encoding ABCA1, APOB, CELSR2, CETP, DOCK7,
GALNT2, GCKR, HMGCR, LDLR, LIPC, LIPG, LPL, MLXIPL, NCAN, PCSK9 and
TRIB1, and three genetic regions with multiple associated genes including MVK-MMAB,
APOA5-APOA4-APOC3-APOA1 and APOE-APOC1-APOC4-APOC2. Many of these
have also been consistently associated with lipid levels in candidate gene studies reported
over the past 30 years12,13. Currently identified common loci explain only a small fraction
of variation in the concentration of lipids within the population. In contrast to rare variants
with major effects such as those underlying familial hypercholesterolemia, common variants
improve the prediction of cardiovascular disease only marginally in terms of the clinical
classification of patients14. As the genetic profiles studied are far from complete, there is
substantial room for further characterization of genetic profiles influencing serum lipid
levels.
GWA studies published so far have generally included subjects ascertained for the presence
or absence of a disease or trait component (particularly diabetes). Compared to population-
based cohorts, such ascertainment has the potential to generate bias with respect to both the
detection of associations and the estimation of their population-level impact. Here we report
the results of GWA analysis of 16 European studies (total number of persons 17,798-22,562,
depending on the lipid trait studied), representing population-based cohorts. We combined
these large cohorts to identify loci affecting serum levels of HDL, LDL, TG as well as total
cholesterol (TC) across different European populations. We further examined whether the
associated lipid loci showed any sex-specific differences in effect size, as well as their
impact on cardiovascular morbidity in elderly cohorts.
RESULTS
Screening for new loci associated with lipid levels
Meta-analysis of GWA data from the ENGAGE cohort datasets (Table 1) with respect to the
levels of the four principal lipid phenotypes (LDL, HDL, TC, TG) resulted in 162 signals
with P value <5 × 10-8 (full list provided in Supplementary Table 1 online; genome-wide
association plots in Supplementary Fig. 1 online). These 162 SNPs represent a total of 22
chromosomal loci associated with serum lipid levels in the general population (Table 2). Of
these, 16 regions have been identified in earlier GWA studies and 6 are newly identified. As
expected given the high correlations observed between some of the lipid fractions
(correlation up to 0.89 for LDL and TC in the Northern Finnish Birth Cohort), several of the
loci were associated with multiple lipid measures.
For TC, we found 11 regions showing genome-wide significant evidence for association. Of
these, eight have previously been implicated in GWA scans for LDL or TG (Table 2), and
three (ABCG5 (rs6756629), FADS2-FADS3 (rs174570) and TMEM57 (rs10903129))
represent new loci. For LDL, out of eight associated loci, three (ABCG5 (rs6756629),
DNAH11 (rs12670798) and FADS2-FADS3 (rs174570)) were not known before. For HDL,
eight regions showed genome-wide significant results including two newly identified
regions, CTCF-PRMT7 (8 SNPs associated with P < 5 × 10-8) and MADD-FOLH1 (9 SNPs
associated). For TG, all seven regions showing genome-wide significance in the current
study were previously implicated in the control of serum lipid levels (DOCK7, APOB,
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GCKR, BAZ1B-BCL7B-TBL2-MLXIPL region, LPL-SLC18A1 region, BUD13-APOA
cluster (A1/A4/A5/C3), CEACAM16-TOMM40-APOE region). Within two of the newly
identified loci, there was only one SNP reaching genome-wide significance. However, for
both regions, there were multiple additional SNPs with suggestive association (not reaching
the level of 5 × 10-8, see Supplementary Fig. 2 online). When comparing the effects of the
22 SNPs across the different populations, we found that all SNPs showed consistent
evidence for association across European populations (Supplementary Fig. 3 online). As an
example of similarity of effects across the cohorts, Figure 1 shows the forest plot of effects
for rs7395662 (MADD-FOLH1) on high-density lipoprotein. The estimated effect sizes are
very similar across the cohorts, particularly in the largest cohorts. The effects were also
similar for the two sexes.
Characterization of associated loci
We also evaluated the potential relevance for biological pathways related to lipid
metabolism by carrying out a genome-wide association network analysis (GWANA) of
associated SNPs. GWANA uses the ranking of associated genes together with their
biological pathway information based on Gene Ontology to list pathways that are enriched
among the most highly associated genes. This is analogous to the way pathway analyses of
signals obtained in genome-wide transcript data are analyzed15. We present GWANA
results using data for GWA-identified SNPs associated with TC (Fig. 2). The GWANA-
associated genes for TC, tagged by the best SNP per gene, showed statistically significant
clustering to highly relevant pathways shown in green in Figure 2: two major pathway trees
linked the TC-associated genes to cholesterol and sterol metabolism, lipid transporters and
even nutrient response. We present the data of the GWANA analyses for other lipids in the
Supplementary Table 2 and Supplementary Figure 4 online.
When we tested for effect difference between males and females among the associated loci,
rs3846662 in HMGCR (effect in males = 0.049, effect in females = 0.117; P = 0.0013, Fig.
3) and rs2304130 NCAN (effect in males = -0.234, effect in females = -0.110; P = 0.0019)
showed significant differences in effect size for TC. Similarly, rs2083637 in LPL showed
different effects for HDL (effect in males = 0.149, effect in females = 0.079; P = 0.0060),
even after correction for multiple testing. Sex-specific P-value plots for the four lipid traits
are shown in Supplementary Figure 5 online.
Genetic risk scores
Next, on the basis of loci discovered in our own and previous genome-wide association
findings, we constructed genetic risk scores (profiles) for TC, HDL, LDL and TG in the
three large cohorts (NFBC, Rotterdam Study and MZ twins, n = 12,361). The scores were
computed as weighted sums of the number of lipid level-increasing (or decreasing for HDL)
alleles carried by a person. To eliminate bias arising from use of the same data both for
defining the optimal weights and for estimating the population effects, we based the
weighting on the estimated effect sizes of each allele across all the study cohorts after
excluding the study in which the risk score was being applied.
For the TC risk score, we used the 11 SNPs listed in Table 2. For the HDL risk score, we
used the 8 SNPs showing genome-wide significance in this study (Table 2) and rs2144300
tagging the previously reported GALNT2 locus, rs2338104 tagging the KCTD10-MVK-
MMAB region7, and rs12272004 tagging the APOA1/A4/A5/C3 region6. For the LDL risk
score, we used eight SNPs showing genome-wide significance in this study (Table 2) plus
rs11206510 in PCSK9 and rs16996148 in NCAN-CILP2 (ref. 7) loci. For the TG score, in
addition to the seven SNPs shown in Table 2, we used three SNPs from TRIB1
(rs17321515), NCAN-CILP2 (rs16996148) and LIPC (rs4775041)7. In the three cohorts, the
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genetic risk profile explained 3.9% of the total variance in sex- and age-adjusted TC.
Similarly, genetic risk profiles explained 4.8%, 3.4% and 3.0% of age-adjusted variances in
HDL, LDL and TG, respectively. In Table 3 and Supplementary Figure 6 online, we show
these variance decompositions separately for both sexes in the three cohorts (total n =
12,361). Because the three cohorts differ appreciably in terms of age distribution, results are
reported separately for NFBC (all participants aged 31), MZ twins (mean age 50) and the
Rotterdam Study (mean age 69). The genetic risk profiles seem to account for similar
proportions of variance regardless of age patterns except for LDL, where the proportion of
variance explained by associated genes seems to drop in the older cohorts. The lipid
variance explained by the genetic risk score approaches that explained by the body mass
index (BMI), a traditional risk factor for cholesterol.
Lipid values are widely applied predictors for cardiovascular diseases in the clinical setting.
One of our older cohorts, the Rotterdam Study (all subjects over 55 years of age) had
follow-up for clinical events. In this cohort, we could test for association between the
genetic risk profiles and end-points of clinical relevance, including intima media thickness
(IMT) and incident coronary heart disease (CHD). Of the five risk profiles (TC, HDL, LDL,
TG specific and a ‘combined profile’ including all associated SNPs for the four traits), the
TC profile and the combined profile were most strongly associated with relevant clinical
outcomes. The TC risk profile was significantly (P < 0.001) associated with clinically
defined hypercholesterolemia (serum cholesterol over 6.5 mmol/l), suggesting that the joint
testing of the loci will be clinically relevant to ascertain high risk groups. TC risk scores
improved the prediction of hypercholesterolemia beyond that achieved with age, sex and
body mass index (AUC (area under the receiver-operating-characteristic curve) increase
from 0.63 (95% CI = 0.61-0.64) to 0.66 (95% CI = 0.65-0.67)). The TC genetic risk score
was significantly associated with IMT (P = 0.001). This association was still significant (P =
0.043) after adjustment for circulating levels of TC. In line wit these findings and those of
others14, neither the TC risk scores nor the other four genetic risk scores improved the
prediction of incident CHD. The TC genetic risk score was also associated with risk of
incident CHD (P = 0.042), but the association did not remain significant after addition of
circulating levels of TC into the model, implying that TC levels are in the causal pathway in
between the genetic variants and the disease.
DISCUSSION
We aimed to identify loci involved in the regulation of circulating lipid levels. Screening for
increased circulating lipid levels and early treatment with statins is one of the key strategies
in the prevention of cardiovascular risk in clinical practice, and dietary change is the primary
prevention strategy at the population level. Potential new lipid-associated loci could
contribute to these prevention strategies. We used GWA data from 16 cohorts, including
three large cohorts each over 3500 samples (NFBC, Rotterdam Study and NTRNESDA) and
13 smaller cohorts from across Europe. We have identified six new risk loci and confirmed
16 regions previously associated with lipid metabolism in earlier GWA studies6-8,14. All
newly identified regions showed robust effects across the study cohorts, which had different
age distributions, geographic origins and lifestyle patterns (Supplementary Fig. 3). It is of
interest that 16 out of 22 loci had been previously identified in case-control studies, most
with samples enriched by type 2 diabetes cases, suggesting that effects seen in diabetic
individuals are independent of the disease. It remains to be determined whether effects of the
new loci we identified are also observed in individuals with diabetes.
We have compared the effect estimates obtained in our meta-analysis and those reported in
Kathiresan et al., which is a Swedish population-based study14. From 24 SNPs presented in
Kathiresan et al., all but two (rs11591147 and rs599838) were typed in at least one
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population used in the present study. For most loci, similar estimates of effect sizes were
obtained from our population-based cohorts and the cohort used by Kathiresan et al.
However, the effect of rs6511720[T] in LDLR on LDL was estimated as -0.26 ± 0.02 s.d. by
Kathiresan et al. and -0.15 ± 0.03 s.d. in our analysis; this effect difference is significant
(nominal P = 0.002) and remained so after multiple-testing correction for the 22 SNPs
compared.
Our study samples were compiled from the population cohorts of the ENGAGE project,
which aims to provide an infrastructure to combine large study samples and datasets across
populations of European origin. Out of the 22 associated loci, a total of 11 were associated
with TC, including three new ones in addition to 8 loci earlier associated with the level of
LDL. Out of three new TC-associated loci, ABCG5 (rs6756629) and FADS2-FADS3 were
associated with both TC and LDL, whereas TMEM57 only showed genome-wide significant
association with TC and a much weaker association with LDL (Table 2).
Among the six newly identified lipid-associated loci, two include genes encoding proteins
known to be involved in lipid metabolism based on either the data from experimental animal
studies or monogenic human diseases. One of them is part of the FADS2-FADS3 (fatty acid
desaturase 2 and 3) gene cluster, a gene family encoding proteins that regulate desaturation
of fatty acids through the introduction of double bonds between defined carbons of the fatty
acyl chain. The second obvious functionally relevant gene is ABCG5 (ATP-binding cassette
transporter family member 5). The corresponding protein functions as a half-transporter,
dimerizing with ABCG8 to form a functional complex necessary for efflux of dietary
cholesterol and noncholesterol sterols from the intestine and liver. Mutations in ABCG5 are
known to cause the rare monogenic disorder sitosterolemia, characterized by abnormal
absorption of cholesterol and other sterols (MIM210250), and variants of this gene have
been shown to regulate blood cholesterol levels (and risk of gallstones) in humans16.
For the other four newly identified loci, the role in lipid metabolism is less obvious. The
first, here assigned as MADD-FOLH1 locus of chromosome 11p, represents a gene desert
close to the centromere with no known gene on the 500-kb flanking region, and the two
genes flanking the locus, MADD and FOLH1, have not been implicated in lipid metabolism.
However, NR1H3, or LXRA, an orphan member of the nuclear receptor superfamily, is
located just 0.5 kb telomeric of MADD and an associated SNP in this gene was reported in
the NFBC cohort17. The liver X receptors (LXRs) are established mediators of lipid-
inducible gene expression. At the second locus, the CTCF-PRMT8 gene encodes a
transcriptional regulator potentially involved in hormone dependent gene silencing. At the
third, the DNAH11 gene encodes a member of the dynein heavy chain family known to be
involved in the movements of cellular cilia. Finally, TMEM57 encodes a membrane protein
with poorly characterized function. Further studies are needed to examine the potential role
of these or neighboring genes in lipid metabolism.
None of the published GWA studies have addressed the potential sex-based difference in
genetic risk profiles for lipids. Here we found significantly different sex-specific effects for
some genes, as expected from epidemiological and clinical data18. Lipid values for males
and females are known to differ, as does the prevalence of cardiovascular diseases19. The
two loci showing the strongest evidence for sex-based differences in effect size are those
containing HMGCR (3-hydroxy-3-methylglutaryl-Coenzyme A reductase (HMGCoA) and
NCAN (neurocan). HMGCR is the rate-limiting enzyme for cholesterol synthesis and the
drug target for statins20, commonly used for treating high LDL values21. Variants in
HMGCR have recently been associated with reduced efficacy of pravastatin therapy22.
Previous GWA studies have provided compelling evidence that common intronic variants of
this gene are associated with LDL cholesterol, with 0.1 mmol/l difference between two
Aulchenko et al. Page 6
Nat Genet. Author manuscript; available in PMC 2009 July 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
homozygote classes7. The second gene with a potential sex-specific effect, NCAN, encodes
a chondroitin sulfate proteoglycan thought to be involved in the modulation of cell adhesion
and migration. The locus flanking the NCAN gene has previously been associated with both
LDL and TG8.
Just as for sex-associated differences, we might have expected to see differences in genetic
profiles among European populations with large differences in average levels of serum
lipids. Notably, the direction of the change in lipid level as well as the effect of the
associated variants was for most of 22 loci quite similar across the various European
populations. This could indicate that the contribution of lifestyle and environmental
variation may have limited impact on observed between-population differences in lipid
levels. More likely, perhaps our study design selected for detection of signals that show
consistent effects across populations, and was biased against the identification of loci that
have substantial heterogeneity of effect size.
Lipid-associated loci described in this study were not significantly associated with BMI in
our cohorts, although obesity itself is correlated with lipid levels23. The proportion of
variance explained by all 22 loci for lipid levels in our general population samples was
comparable to that explained by BMI, although the percentage of variance explained is still
small.
To evaluate the clinical relevance of genetic ‘risk profiles’, we carried out a prospective
analysis of the oldest cohort data. The genetic risk scores were predictive of dyslipidemia,
improving discriminative accuracy, measured by AUC, from 63% (age, sex and BMI alone)
to 66%. This improvement due to the genetic score is bigger than in most recently reported
AUCs24 and suggests that genetic profiles may be useful for the early detection and
treatment of dyslipidemias and related cardiovascular risk, thus enabling early preventive
strategies. In line with earlier data14, we saw an improvement in CHD risk classification
when adding the genetic profile to the ‘traditional’ clinical risk factors of lipid values, age,
BMI and sex (such as Framingham25 or QRISK scores26). One noteworthy observation
from our study is that the genetic risk profile identified for TC seems to represent the most
informative score when relating the data to clinically relevant outcomes such as clinical
hypercholesterolemia, intima media thickness and coronary heart disease. Until now, none
of the GWA studies had targeted the TC phenotype (which represents a composite of LDL,
HDL and VLDL cholesterol) for examination. Our findings suggest that the genetic score
for TC is the most powerful option for predicting atherosclerosis and CHD.
We report here the first GWA study for serum lipid levels conducted in population cohorts,
not ascertained for any specific disease. We identified a total of 22 loci, including six new
ones. Some of these loci show different impact for males and females. The genetic risk
scores constructed from the associated genes for each lipid trait provided explanatory value
comparable to that of BMI. These genetic profiles seem to improve the identification of
those at high risk of dyslipidemia but do not yet improve the prediction of atherosclerosis
and CHD over classical risk factors.
METHODS
Study cohorts
We provide basic features of the population samples as well as the distribution of lipid
values within individual cohorts and in the total study sample in Table 1. Informed consent
was obtained from all study subjects and study protocols were approved by an appropriate
local committee.
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Twin sample—The Danish, Dutch, Finnish, Italian, Norwegian and Swedish national twin
cohorts, together with St. Thomas’ twin cohort in Great Britain and an Australian twin
cohort, form the basis of the GenomEUtwin project, a collection of over 300,000 twins27.
From these cohorts, we selected female monozygotic pairs aged 20-80 years with blood lipid
measurements available on both members. The sample consisted of pairs from Australia
(459 pairs), Denmark (173 pairs), Finland (152 pairs), The Netherlands (331 pairs), Sweden
(301 pairs) and the UK (462 monozygotic (MZ) pairs and 3,000 dizygotic (DZ) pairs). DNA
samples from one member of each monozygotic twin pair were used for genotyping (twin
cohort details; S.R. et al., unpublished data).
Northern Finnish Birth Cohort of 1966 (NFBC1966)—Mothers expected to give birth
in the two northern provinces of Oulu and Lapland in 1966 were enrolled in NFBC1966 (n =
12,058 live births)28. At the 31-year clinical examination, participants provided fasting
blood samples for evaluation of the metabolic measures that are the focus of the current
study (n = 5654), and DNA was also extracted from the blood samples provided at this time.
All DNA samples for the Illumina Infinium 370cnvDuo array were prepared for genotyping
by the Broad Institute Biological Sample Repository (BSP) as a part of STAMPEED
consortium funded by the US National Heart, Lung, and Blood Institute.
Rotterdam Study—The Rotterdam Study29 is a prospective cohort study that started in
1990 in Ommoord, a suburb of Rotterdam, among 10,994 men and women aged 55 and
over. The main objective of the Rotterdam Study is to investigate the prevalence and
incidence and risk factors for cardiovascular, neurological, locomotor and ophthalmologic
diseases in the elderly. Baseline measurements were obtained between 1990 and 1993. All
participants were subsequently examined in follow-up examination rounds every 2-3 years.
For this study, we used 6,000 participants for whom GWA data were available; nonfasting
total cholesterol and HDL was available for most study participants; fasting TC, HDL and
TG were available for 2,300 participants of Rotterdam Study 3 (1997-1999). LDL was
estimated using the Friedewald formula, eLDL = TC - HDL - 0.456 TG (mmol/l), using
nonfasting samples only30. Nonfasting TC and HDL and fasting TG and estimated LDL
were used in this study.
EUROSPAN—The European Special Populations Network (EUROSPAN) consortium
consists of five population samples: (i) the Erasmus Ruchpen Family (ERF) study conducted
in The Netherlands, (ii) the MICROS study conducted in Italy, (iii) the Northern Swedish
Population (NSP), (iv) the Orkney Complex Disease Study (ORCADES; Scotland) and (v)
the Vis study conducted in Croatia. All EUROSPAN cohorts were genotyped using Illumina
317K platform. A brief description of each population is given below.
The ERF study31 is a family-based study that includes over 3,000 participants descending
from 22 couples living in the Rucphen region in the 19th century. Participants were
clinically examined in person and provided fasting blood samples for metabolic
measurements and DNA extraction. The 800 participants included in this study consisted of
the first series of participants for whom GWA data were available.
The MICROS study32 is part of the genomic healthcare program ‘GenNova’. The MICROS
was an extensive survey carried out during 2001-2003 in three villages of the Val Venosta
on the populations of Stelvio, Vallelunga and Martello. Information on the health status of
participants was collected through a standardized questionnaire, and lipids were measured
with standard blood analyses. The 1,100 participants included in this study are those for
whom both phenotypic and GWA data were available.
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The Northern Swedish Population Health Study (NSPHS) represents a family-based
prospective population study located in the parish of Karesuando, in the subartic region of
the County of Norrbotten. This parish has about 1,500 inhabitants, 740 of whom participated
in the study. Historic population accounts show that there has been little immigration or
other dramatic population change in this area during the last 200 years. The study includes a
comprehensive health investigation and collection of data on family structure, lifestyle, diet,
medical history and samples for clinical chemistry, RNA and DNA analyses.
The Orkney Complex Disease Study (ORCADES) is an ongoing family-based genetic
epidemiology collection in the isolated Scottish archipelago of Orkney. Genetic diversity is
decreased compared to mainland Scottish samples, consistent with the high extent of
endogamy historically. Samples from 800 individuals from a subgroup of ten islands with
age 18-100 years were included in the present study.
The Vis study33 includes unselected Croatians, aged 18-93 years, who were recruited during
2003 and 2004 from the villages of Vis and Komiza on the Dalmatian island of Vis.
Biochemical and physiological measurements were done, detailed genealogies
reconstructed, questionnaire of lifestyle and environmental exposures collected, and blood
samples and lymphocytes extracted and stored for further analyses. The 800 participants
included in this study were these who had both GWA and phenotypic data available.
NTR/NESDA—The NTR/NESDA samples include Dutch twin families from the
Netherlands Twin Register (NTR) and participants from the Netherlands Study of
Depression and Anxiety (NESDA)34. We selected 1,862 unrelated participants with a
depression or anxiety related diagnosis (MDD) and 1,857 unrelated controls at low liability
for MDD for genome-wide genotyping with support of the US Foundation for the National
Institutes of Health Genetic Association Information Network (FNIH/GAIN). This is the
only cohort with some trait-specific ascertainment. Baseline characteristics of NTR and
NESDA participants have been previously described34. The average age of participants was
43.6 years (65% women) and lipids were measured from fasting blood samples. Genotyping
was conducted by Perlegen Sciences.
Cooperative health research in the Region of Augsburg (KORA)—The KORA
research project has evolved from the WHO MONICA study (Monitoring of Trends and
Determinants of Cardiovascular Disease). The KORA genome-wide association study was
done using samples from the KORA S3 survey, which is a population-based sample from
the general population living in the region of Augsburg, Southern Germany35. Standardized
examinations of 4,856 participants, aged 25 to 74 years, were done during 1994-1995 (ref.
35) with followup examination of 3,006 participants in 2004-2005 (KORA F3). For the
genome-wide study we selected 1,644 subjects from KORA S3/F3.
Genotyping
Most of the study cohorts used Infinium II assay36 on the HumanHap300-Duo Genotyping
BeadChips (Illumina), although other chips, including Affymetrix, were used for 15% of the
samples. Full details are given in Table 1. For the purpose of future meta-analysis, quality
control was restricted to individual-level checks, done in each study group separately. The
overall recommendation was to exclude individuals with low call rate, excess
heterozygosity, mismatch between reported and genetically determined sex, SNP calls
indicating simultaneous presence of two X and a Y chromosomes, or non-European
ancestry. We used the identity-by-descent (IBD) analysis option of PLINK37 or the genomic
kinship option of GenABEL38 to determine relatedness among our sample subjects, and to
identify sample duplications. In population-based samples, this information was also used to
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identify sample contamination (subjects who seemed to be related to nearly everyone in the
sample) and unexpected close relatives. If the sample duplication issue could not be resolved
by external means, both samples were excluded. People of non-European ancestry were
identified using principal components analysis of the IBD or genomic kinship matrices39
and excluded from analysis. Full details of the ENGAGE quality control and analysis report
format recommendations can be found at the ENGAGE website (see URLs section below).
Before meta-analysis, individual study SNPs were filtered to satisfy call rate >90%, Hardy-
Weinberg equilibrium (HWE) test P value >10-8 and minor allele frequency (MAF) >0.5%.
Statistical analysis
Within each cohort, blood lipid measurements were stratified by sex; in each stratum,
outcomes were adjusted for age using a linear regression model and the residuals were
standardized and used as outcome measures in the subsequent sex-specific association
testing. In monozygotic twins, the mean of the two lipid measurements in a pair was used as
the raw phenotype, thereby halving error variance and increasing power for association
analysis (S.R., unpublished data). Triglycerides were log-transformed before regressing in
all cohorts. For genotype-lipid association analyses, we assumed an additive mode of
inheritance. Association analyses were conducted using GenABEL38 and PLINK37.
The results from all cohorts were combined into a fixed-effects meta-analysis with
reciprocal weighting on the square of standard errors of the effect size estimates, using the
MetABEL package. Genomic control correction40 was applied to correct standard errors
before pooling. All population-based cohorts showed low overdispersion (λ < 1.05),
whereas family-based cohorts (ERF, NSP, MICROS, ORCADES, Vis), as expected, showed
larger values of λ. In the pooled data, λ was 1.02 for TC, LDL and HDL, and 1.01 for TG.
The difference between estimated effects in males and females was tested using the t-test.
Population heterogeneity of effects was assessed using Cochran’s Q test.
The ranking of the SNP associations for each trait was the input for the GWANA pathway
analysis. These SNPs were mapped to the human genes using cross-references in the
Ensemble database and the genes were queried for their Gene Ontology annotations. The
topology of the Gene Ontology tree was fully used by enumerating all available routes
toward the root of the Gene Ontology tree and adding all available vertexes as Gene
Ontology annotations of the given gene. For detecting the Gene Ontology gene groups
(‘pathways’), a cumulative score based on how extreme the observed combination of
associated genes in a given pathway is is compared to the all associated genes and their
pathways. The more genes a pathway had among all top-ranked genes, the smaller the
cumulative score. The observed cumulative scores were further compared with permuted
values, where the original SNP-based P-value ranks were permuted and the cumulative
scores were recalculated for each permutation round. The top pathways and their permuted
scores are reported in the Supplementary Table 2 and Supplementary Figure 4.
In the Rotterdam Study, where we tested effects of risk scores on lipid levels, intima media
thickness and coronary heart disease, ~2.5 million SNPs were imputed using release 22
HapMap CEU population as reference. The imputations were done using MACH
software41. The quality of imputations was checked by comparing imputed and actual
genotypes at 78,844 SNPs not present on the Illumina 550K array for 437 individuals for
whom these SNPs were directly typed using the Affymetrix 500K chip. Using the ‘best
guess’ genotype for imputed SNPs, we calculated a concordance rate of 99% for SNPs with
R2 (ratio of the variance of imputed genotypes to the binomial variance) quality measure
greater than 0.9; concordance was still high (94%) when R2 was between 0.5 and 0.9. All
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SNPs analyzed for association with lipid levels, except two, had R2 > 0.96; two exceptions
were rs4775041 (R2 = 0.83) and rs439401 (R2 = 0.65).
Genetic scores were used to assess the proportion of variance explained by lipid genes and
their impact onto clinically relevant outcomes (intima media thickness, coronary heart
disease and dyslipidemia). We used a genetic score defined as a weighted sum of the risk
alleles, with weights proportional to the effect estimates obtained in meta-analysis. Risk
alleles were defined as those increasing levels of TC, LDL or TG, or decreasing the levels of
HDL. Five genetic scores (TC, LDL, HDL, TG and total) were analyzed.
To avoid bias in estimation of the proportion of variance explained by the risk score in a
particular cohort, we re-estimated the weights of the risk score (allelic effects) by meta-
analysis of all cohorts except the one where the proportion was computed afterwards. For
example, when estimating the proportion of variance explained in the Rotterdam Study, we
used allelic effect estimates from meta-analysis of all studies but the Rotterdam Study, and
so on.
We analyzed association of the allele scores with incident CHD and dyslipidemia in the
Rotterdam study using SPSS 15.0. For analysis of incident CHD, we used the Cox
proportional hazards model to estimate hazard ratios and the significance of their deviation
from unity. Association between the genetic risk score and dyslipidemia at baseline was
assessed using logistic regression. Four prediction models were investigated: (i) age and sex;
(ii) age, sex and allele score; (iii) age, sex and clinical variables; and (iv) age, sex, clinical
variables and allele score. The contribution of the allele scores to the prediction of CHD and
dyslipidemia was investigated by comparing the area under the receiver-operating-
characteristic curves (AUC) of the prediction models. AUC estimates were obtained using
the ROC plot function of SPSS, on the basis of the linear predictors obtained from the Cox
proportional hazards analyses and the predicted probabilities from the logistic regression
analyses. Dyslipidemia was defined as total cholesterol levels equal or higher than 6.5
mmol/l.
The proportion of explained variance was assessed in the Rotterdam Study, NFBC66 and
MZ twin cohorts. Because some of these cohorts were matched for sex or age, we stratified
for sex and used residuals from linear regression of the lipid levels on age to estimate the
comparative effect of genetic score and body mass index (BMI). The proportion of variance
attributable to each of the two predictors was assessed by fitting an ANOVA analysis of the
linear regression model (“lm” and “anova” functions of R).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Effect of rs7395662 (MADD-FOLH1) on high-density lipoprotein separately for different
cohorts and sexes.
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Figure 2.
Pathways containing an enrichment of the most strongly associated genes with total
cholesterol (green circles) and their connections.
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Figure 3.
Effect of rs3846662 (HMGCR) on total cholesterol separately for different cohorts showing
different effects for the two sexes.
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